Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999–2014)

Authors: Sen Li, Xi Wen

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Herpes simplex virus types 1 and 2 (HSV1 and HSV2) are infectious agents, and their association with cancer occurrence in human is a controversial topic for decades. We addressed this subject using all available continuous National Health and Nutrition Examination Survey (NHANES) cross-sectional data from 1999 to 2014.

Methods

Eight data cycles (1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010, 2011–2012, and 2013–2014) were employed, and a sample of 8184 female participants was used in this study according to the availability of cancer history and HSV serostatus.

Results

The seroprevalences of HSV1 and HSV2 were 60.73 ± 0.89 and 25.02 ± 0.64, respectively, and the numbers increased with age (P < 0.01). In confounder-adjusted logistic regression analysis, association between HSV1 seropositivity and uterine cancer was identified (adjusted odds ratio-ORadjusted = 6.03; 95% CI: 1.52, 23.87). HSV2 seropositivity was associated with cancer occurrence (ORadjusted = 1.47; 95% CI: 1.01, 2.14), cervical cancer (ORadjusted = 1.72; 95% CI: 1.06, 2.79) and uterine cancer (ORadjusted = 3.49; 95% CI: 1.03, 11.85). Moreover, HSV2 was persistently associated with cervical cancer after further adjusting high-risk human papillomavirus (HPV) as confounder (ORadjusted = 1.90; 95% CI: 1.09, 3.34). Relative risk (RR)-based interaction measurement between HSV2 and HPV on the additive scale suggests higher RR for cervical cancer in participants with seropositivity for HPV only (RRadjusted = 2.98; 95% CI: 1.23, 7.20; P = 0.02), HSV2 only (RRadjusted = 2.79; 95% CI: 1.31, 5.96; P = 0.01) or both viruses (RRadjusted = 3.44; 95% CI: 1.50, 7.86; P < 0.01) when setting participants with seronegativity for both HPV and HSV2 as reference.

Conclusions

The finding of current study provides epidemiological evidence that serostatus of HSV2 can serve as an independent predictor for cervical cancer.
Appendix
Available only for authorised users
Literature
1.
World Cancer Report 2014. World Health Organization 2014, pp. Chapter 5.12.
2.
World Cancer Report 2014. World Health Organization 2014, pp. Chapter 1.1.
3.
National Institutes of Health, National Cancer Institute: PDQ® Cervical Cancer Treatment. Date last modified 2/4/2016.
4.
Haverkos H, Rohrer M, Pickworth W. The cause of invasive cervical cancer could be multifactorial. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2000;54(1):54–9.CrossRef
5.
Macnab JC, Kitchener HC. Sexually transmitted cancers and viruses. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 1989;43(3):167–72.CrossRef
6.
Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis. 2014;209(3):325–33.CrossRefPubMed
7.
8.
Menczer J, Leventon-Kriss S, Modan M, Oelsner G, Gerichter CB. Antibodies to herpes simplex virus in Jewish women with cervical cancer and in healthy Jewish women of Israel. J Natl Cancer Inst. 1975;55(1):3–6.CrossRefPubMed
9.
Mendis LN, Best JM, Banatvala JE. Class-specific antibodies (IgG and IgA) to membrane antigens of herpes simplex type 2-infected cells in patients with cervical dysplasia and neoplasia. Int J Cancer. 1981;27(5):669–77.CrossRefPubMed
10.
Frenkel N, Roizman B, Cassai E, Nahmias A. A DNA fragment of herpes simplex 2 and its transcription in human cervical cancer tissue. Proc Natl Acad Sci U S A. 1972;69(12):3784–9.CrossRefPubMedPubMedCentral
11.
Vonka V, Kanka J, Hirsch I, Zavadova H, Krcmar M, Suchankova A, Rezacova D, Broucek J, Press M, Domorazkova E, et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int J Cancer. 1984;33(1):61–6.CrossRefPubMed
12.
Maitland NJ. The aetiological relationship between herpes simplex virus type 2 and carcinoma of the cervix: an unanswered or unanswerable question? Cancer Surv. 1988;7(3):457–67.PubMed
13.
Wilkinson DE, Weller SK. Herpes simplex virus type I disrupts the ATR-dependent DNA-damage response during lytic infection. J Cell Sci. 2006;119(Pt 13):2695–703.CrossRefPubMedPubMedCentral
14.
Jensen K, Patel A, Larin A, Hoperia V, Saji M, Bauer A, Yim K, Hemming V, Vasko V. Human herpes simplex viruses in benign and malignant thyroid tumours. J Pathol. 2010;221(2):193–200.CrossRefPubMed
15.
16.
Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol. 2003;10(1):108–15.PubMedPubMedCentral
17.
18.
Boyle DC, Smith JR. Infection and cervical intraepithelial neoplasia. International journal of gynecological cancer: official journal of the International Gynecological Cancer. Society. 1999;9(3):177–86.
19.
Kwasniewska A, Korobowicz E, Zdunek M, Skoczynski M, Kwasniewski W, Danilos J, Gozdzicka-Jozefiak A. Prevalence of chlamydia trachomatis and herpes simplex virus 2 in cervical carcinoma associated with human papillomavirus detected in paraffin-sectioned samples. Eur J Gynaecol Oncol. 2009;30(1):65–70.PubMed
20.
Gupta MM, Sharma BK, Singh V, Luthra UK. Immunocytological demonstration of HSV-II antigen on exfoliated cells from precancerous and cancerous lesions of the uterine cervix. Diagn Cytopathol. 1988;4(1):48–9.CrossRefPubMed
21.
Smith JS, Herrero R, Bosetti C, Munoz N, Bosch FX, Eluf-Neto J, Castellsague X, Meijer CJ, Van den Brule AJ, Franceschi S et al: Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002, 94(21):1604–1613.
22.
Franceschi S, Doll R, Gallwey J, La Vecchia C, Peto R, Spriggs AI. Genital warts and cervical neoplasia: an epidemiological study. Br J Cancer. 1983;48(5):621–8.CrossRefPubMedPubMedCentral
23.
Kjaer SK, de Villiers EM, Caglayan H, Svare E, Haugaard BJ, Engholm G, Christensen RB, Moller KA, Poll P, Jensen H, et al. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look. Br J Cancer. 1993;67(4):830–7.CrossRefPubMedPubMedCentral
24.
Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F: GLOBOCAN, cancer incidence and mortality worldwide. 2012.
25.
Looker KJ, Garnett GP, Schmid GP: An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bulletin of the World Health Organization 2008, 86(10):805–812, a.
26.
de Sanjose S, Munoz N, Bosch FX, Reimann K, Pedersen NS, Orfila J, Ascunce N, Gonzalez LC, Tafur L, Gili M, et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer. 1994;56(3):358–63.CrossRefPubMed
27.
Hildesheim A, Mann V, Brinton LA, Szklo M, Reeves WC, Rawls WE. Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. Int J Cancer. 1991;49(3):335–40.CrossRefPubMed
28.
Becker TM, Wheeler CM, McGough NS, Parmenter CA, Jordan SW, Stidley CA, McPherson RS, Dorin MH. Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. JAMA. 1994;271(15):1181–8.CrossRefPubMed
29.
Rawls WE, Tompkins WA, Figueroa ME, Melnick JL. Herpesvirus type 2: association with carcinoma of the cervix. Science (New York, NY). 1968;161(3847):1255–6.CrossRef
30.
Grossarth-Maticek R, Frentzel-Beyme R, Kanazir D, Jankovic M, Vetter H. Reported herpes-virus-infection, fever and cancer incidence in a prospective study. J Chronic Dis. 1987;40(10):967–76.CrossRefPubMed
31.
Pandit AA, Khilnani PH, Powar H, Bhave GG, Chadda NO. Detection of HSV-2 antigen in carcinoma cervix and premalignant conditions by immuno-cytochemistry. J Postgrad Med. 1990;36(4):185–90.PubMed
32.
Koffa M, Koumantakis E, Ergazaki M, Tsatsanis C, Spandidos DA. Association of herpesvirus infection with the development of genital cancer. Int J Cancer. 1995;63(1):58–62.CrossRefPubMed
33.
Bashyal R, Dali S. Study on koilocytosis, X-chromatin and HSV-2 in cervical smears in Nepal. Nepal Medical College journal : NMCJ. 2004;6(1):45–8.PubMed
34.
Misra JS, Srivastava S, Singh U, Srivastava AN. Risk-factors and strategies for control of carcinoma cervix in India: hospital based cytological screening experience of 35 years. Indian J Cancer. 2009;46(2):155–9.CrossRefPubMed
35.
Zereu M, Zettler CG, Cambruzzi E, Zelmanowicz A. Herpes simplex virus type 2 and chlamydia trachomatis in adenocarcinoma of the uterine cervix. Gynecol Oncol. 2007;105(1):172–5.CrossRefPubMed
36.
Peng HQ, Liu SL, Mann V, Rohan T, Rawls W. Human papillomavirus types 16 and 33, herpes simplex virus type 2 and other risk factors for cervical cancer in Sichuan Province, China. Int J Cancer. 1991;47(5):711–6.CrossRefPubMed
37.
Castle PE, Escoffery C, Schachter J, Rattray C, Schiffman M, Moncada J, Sugai K, Brown C, Cranston B, Hanchard B, et al. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotrophic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. Sex Transm Dis. 2003;30(7):575–80.CrossRefPubMed
38.
Lehtinen M, Koskela P, Jellum E, Bloigu A, Anttila T, Hallmans G, Luukkaala T, Thoresen S, Youngman L, Dillner J, et al. Herpes simplex virus and risk of cervical cancer: a longitudinal, nested case-control study in the nordic countries. Am J Epidemiol. 2002;156(8):687–92.CrossRefPubMed
39.
Galloway DA, McDougall JK. The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature. 1983;302(5903):21–4.CrossRefPubMed
40.
Wentz WB, Reagan JW, Heggie AD, YS F, Anthony DD. Induction of uterine cancer with inactivated herpes simplex virus, types 1 and 2. Cancer. 1981;48(8):1783–90.CrossRefPubMed
41.
Anthony DD, Wentz WB, Reagan JW, Heggie AD. Induction of cervical neoplasia in the mouse by herpes simplex virus type 2 DNA. Proc Natl Acad Sci U S A. 1989;86(12):4520–4.CrossRefPubMedPubMedCentral
42.
Dhanwada KR, Garrett L, Smith P, Thompson KD, Doster A, Jones C. Characterization of human keratinocytes transformed by high risk human papillomavirus types 16 or 18 and herpes simplex virus type 2. The Journal of general virology. 1993;74(Pt 6):955–63.CrossRefPubMed
43.
Kulomaa P, Paavonen J, Lehtinen M. Herpes simplex virus induces unscheduled DNA synthesis in virus-infected cervical cancer cell lines. Res Virol. 1992;143(5):351–9.CrossRefPubMed
44.
Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, DeRouen TA, Galloway DA, Vernon D, Kiviat NB. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327(18):1272–8.CrossRefPubMed
45.
Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, Basu J, Tachezy R, Lewis R, Romney S. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87(18):1365–71.CrossRefPubMed
46.
Szostek S, Zawilinska B, Kopec J, Kosz-Vnenchak M. Herpesviruses as possible cofactors in HPV-16-related oncogenesis. Acta Biochim Pol. 2009;56(2):337–42.PubMed
47.
Zhao Y, Cao X, Tang J, Zhou L, Gao Y, Wang J, Zheng Y, Yin S, Wang Y. A novel multiplex real-time PCR assay for the detection and quantification of HPV16/18 and HSV1/2 in cervical cancer screening. Mol Cell Probes. 2012;26(2):66–72.CrossRefPubMed
48.
Kaur P, McDougall JK, Cone R. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames. The Journal of general virology. 1989;70(Pt 5):1261–6.CrossRefPubMed
49.
Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989;8(12):3905–10.PubMedPubMedCentral
50.
51.
Blatt AJ, Kennedy R, Luff RD, Austin RM, Rabin DS. Comparison of cervical cancer screening results among 256,648 women in multiple clinical practices. Cancer cytopathology. 2015;123(5):282–8.CrossRefPubMedPubMedCentral
52.
DiPaolo JA, Woodworth CD, Popescu NC, Koval DL, Lopez JV, Doniger J. HSV-2-induced tumorigenicity in HPV16-immortalized human genital keratinocytes. Virology. 1990;177(2):777–9.CrossRefPubMed
53.
DiPaolo JA, Woodworth CD, Coutlee F, Zimonic DB, Bryant J, Kessous A. Relationship of stable integration of herpes simplex virus-2 Bg/II N subfragment Xho2 to malignant transformation of human papillomavirus-immortalized cervical keratinocytes. Int J Cancer. 1998;76(6):865–71.CrossRefPubMed
54.
Galloway DA, McDougall JK. Alterations in the cellular phenotype induced by herpes simplex viruses. J Med Virol. 1990;31(1):36–42.CrossRefPubMed
55.
Hara Y, Kimoto T, Okuno Y, Minekawa Y. Effect of herpes simplex virus on the DNA of human papillomavirus 18. J Med Virol. 1997;53(1):4–12.CrossRefPubMed
56.
Iwasaka T, Yokoyama M, Hayashi Y, Sugimori H. Combined herpes simplex virus type 2 and human papillomavirus type 16 or 18 deoxyribonucleic acid leads to oncogenic transformation. Am J Obstet Gynecol. 1988;159(5):1251–5.CrossRefPubMed
57.
Jha PK, Beral V, Peto J, Hack S, Hermon C, Deacon J, Mant D, Chilvers C, Vessey MP, Pike MC, et al. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet (London, England). 1993;341(8853):1116–8.CrossRef
58.
Zhao Y, Cao X, Zheng Y, Tang J, Cai W, Wang H, Gao Y, Wang Y. Relationship between cervical disease and infection with human papillomavirus types 16 and 18, and herpes simplex virus 1 and 2. J Med Virol. 2012;84(12):1920–7.CrossRefPubMed
59.
Olsen AO, Orstavik I, Dillner J, Vestergaard BF, Magnus P. Herpes simplex virus and human papillomavirus in a population-based case-control study of cervical intraepithelial neoplasia grade II-III. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 1998;106(3):417–24.CrossRefPubMed
60.
Daling JR, Madeleine MM, McKnight B, Carter JJ, Wipf GC, Ashley R, Schwartz SM, Beckmann AM, Hagensee ME, Mandelson MT, et al. The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1996;5(7):541–8.
61.
Wang Y, Lopez JM, Bolge SC, Zhu VJ, Stang PE. Depression among people with type 2 diabetes mellitus, US National Health and nutrition examination survey (NHANES), 2005-2012. BMC psychiatry. 2016;16:88.CrossRefPubMedPubMedCentral
Metadata
Title
Seropositivity to herpes simplex virus type 2, but not type 1 is associated with cervical cancer: NHANES (1999–2014)
Authors
Sen Li
Xi Wen
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3734-2

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy

Research article

miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4

Research article

miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene

Research article

Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis

Research article

Prognostic consequences of implementing cancer patient pathways in Denmark: a comparative cohort study of symptomatic cancer patients in primary care

Research article

In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits